AUSTIN, Texas & ROCHESTER, Minn.--(BUSINESS WIRE)--Luminex Corporation (Nasdaq: LMNX), the world leader in multiplexed solutions, and Mayo Clinic today announced that they have signed a development licensing agreement that enables Mayo to provide genetic and other testing services to patients using Luminex’s xMAP® technology. The agreement contains collaboration and licensing provisions for the inherited disorder thalassemia and also provides opportunities for additional test content creation.
